Rep. Brad Knott Sells Off Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Representative Brad Knott (R-North Carolina) recently sold shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). In a filing disclosed on February 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Oramed Pharmaceuticals stock on January 10th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 1” account.

Representative Brad Knott also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of CompoSecure (NASDAQ:CMPO) on 1/14/2025.
• Purchased $1,001 – $15,000 in shares of CompoSecure (NASDAQ:CMPO) on 1/10/2025.

Oramed Pharmaceuticals Price Performance

Shares of ORMP opened at $2.11 on Thursday. The firm has a 50 day simple moving average of $2.32 and a 200-day simple moving average of $2.36. Oramed Pharmaceuticals Inc. has a 1-year low of $2.00 and a 1-year high of $3.67. The stock has a market cap of $85.06 million, a price-to-earnings ratio of 19.18 and a beta of 1.66.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. BML Capital Management LLC increased its stake in shares of Oramed Pharmaceuticals by 20.9% during the 4th quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock worth $6,398,000 after purchasing an additional 457,716 shares in the last quarter. Murchinson Ltd. increased its stake in shares of Oramed Pharmaceuticals by 0.5% during the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock worth $4,170,000 after purchasing an additional 8,889 shares in the last quarter. Boothbay Fund Management LLC boosted its position in Oramed Pharmaceuticals by 2.0% during the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock worth $2,045,000 after acquiring an additional 16,857 shares during the last quarter. Peapod Lane Capital LLC acquired a new stake in Oramed Pharmaceuticals during the fourth quarter worth approximately $550,000. Finally, Dimensional Fund Advisors LP boosted its position in Oramed Pharmaceuticals by 143.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 70,190 shares during the last quarter. 12.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 19th.

About Representative Knott

Brad Knott (Republican Party) is a member of the U.S. House, representing North Carolina’s 13th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Knott (Republican Party) ran for election to the U.S. House to represent North Carolina’s 13th Congressional District. He won in the general election on November 5, 2024.

Brad Knott grew up in Raleigh, North Carolina. He earned a J.D. from Wake Forest University. Knott’s career experience includes working as a federal prosecutor in the U.S. Attorney’s Office for Eastern North Carolina.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.